Skip to main content
. 2022 Feb 3;139(5):678–685. doi: 10.1182/blood.2021014085

Table 2.

Univariate analysis for serological response rate, after third vaccination, in patients with CLL

Serological response
Variable Category Positive Negative Total P Odds ratio 95% CI
n (%) n (%)
All patients 41 (23.8) 131 (76.2) 172 (100)
Age at time of vaccination (y) ≤65 12 (36.4) 21 (63.6) 33 (19.2) .060 2.2 0.9-5.3
>65 29 (20.9) 110 (79.1) 139 (80.8)
Sex Female 14 (27.5) 37 (72.5) 51 (29.7) .470 1.3 0.6-3.0
Male 27 (22.3) 94 (77.7) 121 (70.3)
Treatment status Treatment-naïve 16 (40.0) 24 (60.0) 40 (23.3) <.001 4.9 1.9-12.9
On-therapy 12 (12.0) 88 (88.0) 100 (58.1)
Off-therapy 13 (40.6) 19 (59.4) 32 (18.6) 5.0 1.8-14.1
Treatment status Lack of active therapy 29 (40.3) 43 (59.7) 72 (41.9) <.001 5.0 2.2-11.5
On-therapy 12 (12.0) 88 (88.0) 100 (58.1)
Binet stage A 16 (40.0) 24 (60.0) 40 (72.7) .360 1.8 0.4-8.4
B or C 4 (26.7) 11 (73.3) 15 (27.3)
IGHV mutational status Mutated 9 (22.0) 32 (78.0) 41 (36.6) .778 1.2 0.4-3.2
Unmutated 14 (19.7) 57 (80.3) 71 (63.4)
FISH Normal 8 (24.2) 25 (75.8) 33 (22.9) .910
del(13q) 8 (21.1) 30 (78.9) 38 (26.4) 1.2 0.3-4.2
Trisomy 12 5 (21.7) 18 (78.3) 23 (16.0) 1.2 0.3-4.9
del(11q) 4 (14.3) 24 (85.7) 28 (19.4) 1.9 0.4-8.9
del(17p) 5 (22.7) 17 (77.2) 22 (15.3) 1.1 0.3-4.7
Treatment protocol BTK inhibitor 9 (15.3) 50 (84.7) 59 (59.0) .499 2.2 0.6-10.4
Venetoclax ± anti-CD20 antibody 3 (7.7) 36 (92.3) 39 (39.0)
Others 0 (0.0) 2 (100) 2 (2.0) *NC
Anti-CD20 (last treatment) ≥12 mo 15 (22.7) 51 (77.3) 66 (70.2) .033 7.9 1.25-48.9
Within <12 mo 1 (3.6) 27 (96.4) 28 (29.8)
Serum IgG level (mg/dL) ≥550 28 (26.9) 76 (73.1) 104 (68.4) .047 2.58 1.02-7.29
<550 6 (12.5) 42 (87.5) 48 (31.6)
Serum IgM level (mg/dL) ≥40 5 (15.6) 27 (84.4) 32 (21.2) .337 0.6 0.2-1.9
<40 28 (23.5) 91 (76.5) 119 (78.8)
Serum IgA level (mg/dL) ≥80 25 (38.5) 40 (61.5) 65 (42.8) <.001 5.4 2.2-13.9
<80 9 (10.3) 78 (89.7) 87 (57.2)
*

Due to a limited number of patients who received other treatments, an odds ratio was not calculated (NC).